Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.240
-0.010 (-0.80%)
At close: Jun 26, 2026, 4:00 PM EDT
1.240
0.00 (0.00%)
Pre-market: Jun 29, 2026, 5:57 AM EDT
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).
It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.
Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc.
| Country | Canada |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Joseph Oliveto |
Contact Details
Address: 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montreal, QC H4M 2X6 Canada | |
| Phone | 514 336 0444 |
| Website | milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Executive Director |
| Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor and Member of Scientific Advisory Board |
| Jeffrey Nelson | Chief Operating Officer |
| David Sandoval | General Counsel and Chief Compliance Officer |
| Roshan Girglani | Vice President of Marketing |
| Jeff Moore | Vice President of Sales |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 15, 2026 | 8-K | Current Report |
| May 22, 2026 | EFFECT | Notice of Effectiveness |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |